For the Inventor, By the Inventor

Enter assignee name

Lexington, MA, United States of America

Shire Human Genetic Therapies, Inc.

USPTO Granted Patents = 86

CIPO Patents = 3

EPO Patents = 57

Trademarks = 15

Forward Citations = 596

Loading Chart...

Loading Chart...

131 inventors (with patents filed for the assignee):

Zahra Shahrokh (15 out of 38 patents)

Michael F Concino (15 out of 27 patents)

Jing Pan (14 out of 18 patents)

4. Pericles Calias (13 out of 29 patents)

5. Michael W Heartlein (13 out of 175 patents)

6. Gaozhong Zhu (9 out of 13 patents)

7. Teresa Leah Wright (9 out of 13 patents)

8. Muthuraman Meiyappan (9 out of 12 patents)

9. Angela Norton (8 out of 12 patents)

10. Bettina Strack-Logue (8 out of 11 patents)

11. Kris Lowe (7 out of 8 patents)

12. Frank DeRosa (7 out of 144 patents)

13. Richard Pfeifer (7 out of 9 patents)

14. Lawrence Charnas (7 out of 10 patents)

15. Thomas Mccauley (6 out of 15 patents)

Core Competencies:

Duchenne Muscular Dystrophy

Bile Acid Recycling Inhibitors

CNS Delivery

Gene Therapy

Lysosomal Enzymes

Antibody Therapeutics

Mucopolysaccharidosis

Alpha-Galactosidase Deficiency

Therapeutic Fusion Proteins

Intrathecal Delivery

Peptide Linkers

Lipid Formulations

86 patents: Sort by Forward Citations

1. 12435146 - Anti-Flt-1 antibodies for treating Duchenne muscular dystrophy (2025-10-07),

2. 12350267 - Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases (2025-07-08),

3. 12145959 - Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease (2024-11-19),

4. 11471516 - CNS delivery of therapeutic agents (2022-10-18),

5. 11376251 - Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases (2022-07-05),

6. 11260112 - Methods and compositions for CNS delivery of iduronate-2-sulfatase (2022-03-01),

7. 11229661 - Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases (2022-01-25),

8. 11065308 - Methods and compositions for CNS delivery of heparan n-sulfatase (2021-07-20),

9. 11065307 - Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety (2021-07-20),

10. 11033459 - Modular vial adapter (2021-06-15),

11. 11013864 - Small unit dosage plunger rod stops (2021-05-25),

12. 10967073 - Glucocerebrosidase gene therapy for Parkinson's disease (2021-04-06),

13. 10896749 - Drug monitoring tool (2021-01-19),

14. 10787515 - Anti-Flt-1 antibodies for treating duchenne muscular dystrophy (2020-09-29),

15. 10760112 - Enzymatic activity assays for glucocerebrosidase (2020-09-01),

Shire Human Genetic Therapies, Inc. is a biotechnology company focused on developing innovative therapies for genetic disorders. With a commitment to improving the lives of patients and their families, Shire's research and development efforts primarily target rare and specialty conditions. Through collaboration with healthcare professionals and advocacy groups, Shire aims to bring forward transformative treatments and solutions with the potential to create lasting impact in the field of genetic therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

86 Patents

#11 in Lexington, MA

#230 in Massachusetts

#4,191 in US

#8,629 in the World

Lexington, MA, United States of America

Shire Human Genetic Therapies, Inc.

Forward Citations = 596

131 inventors:

Zahra Shahrokh (15 out of 38 patents)

Michael F Concino (15 out of 27 patents)

Jing Pan (14 out of 18 patents)

4. Pericles Calias (13 out of 29 patents)

5. Michael W Heartlein (13 out of 175 patents)

Please report any incorrect information to support@idiyas.com

Loading…